financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of Cintas Corporation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of Cintas Corporation
May 1, 2024 6:29 AM

09:05 AM EDT, 05/01/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target to $620 from $550, 38.4x our FY 25 (May) EPS outlook (adjusted to $16.15 from $16.37; we lift FY 24's estimate to $14.90 from $14.65), above the company's five-year forward P/E multiple average. A beat on earnings and raised guidance is driving today's positive movement in share price. CTAS posted Feb-Q EPS of $3.84 vs. $3.18 (+22% Y/Y), $0.26 above consensus. Feb-Q sales were roughly in line with expectations, up 10% Y/Y (an increase of 8% on an organic basis). Margin performance drove earnings expansion during the quarter, with operating income margin widening by 120 bps to 21.6%. Profitability benefited from volume growth, technology improvements, and gains from investment into operational efficiencies. Investment into route optimization and plant equipment utilization are bearing fruit. Despite the solid quarter and our positive view of CTAS's execution on margins and sales expansion, we view valuation as extended, with a forward P/E of 40x at nearly double that of the S&P 500.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of The Goldman Sachs Group
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of The Goldman Sachs Group
Oct 14, 2025
02:40 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $850, applying a forward P/E of 15.6x our 2026 earnings estimate compared to the five-year historical average for normalized EPS at 15.5x. We...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Copyright 2023-2026 - www.financetom.com All Rights Reserved